Do Allergy Drops Work? SLIT Efficacy, Evidence and What to Expect

For most major allergens, allergy drops (SLIT) and allergy shots (SCIT) produce broadly comparable symptom relief. The most rigorous network meta-analysis (Nelson et al., J Allergy Clin Immunol Pract, 2015) found no statistically significant efficacy difference between SLIT-tablet and SCIT for grass pollen — symptom SMD difference of 0.0145, with confidence intervals fully overlapping zero. For house dust mites, some indirect analyses suggest SCIT may have a modest edge (Nelson, 2021 network meta-analysis found SCIT statistically outperforming SLIT drops but not tablets for HDM). For allergens where FDA-approved SLIT tablets exist (grass, ragweed, HDM), the evidence supports treating drops and shots as broadly equivalent alternatives. For polysensitized patients needing multi-allergen treatment or allergens without approved tablets (cat, mold), SCIT currently has more robust evidence.

FDA-approved SLIT tablets (Grastek, Ragwitek, Oralair, Odactra) are standardized biological products that went through full Phase III clinical trials before approval — the same regulatory pathway as pharmaceutical drugs. They are available for four specific allergens: timothy grass, short ragweed, 5-grass mix, and house dust mites. Custom-compounded SLIT drops, by contrast, are prepared by compounding pharmacies using allergen extracts originally licensed for injection use, then prescribed at sublingual doses in an off-label manner. In the US, compounded drops are not FDA-approved as a route of administration, though they are standard care in Europe and have been used by 30-40% of US allergists for multi-allergen mixes. The evidence base for tablets is larger and more standardized; the evidence for drops is meaningful but less rigorous by US regulatory standards.

Most patients begin noticing symptom improvement within the first allergy season after starting SLIT, often within 3-6 months of consistent daily dosing. FDA-approved SLIT tablets show within-first-season improvement when started at least 4 months before peak pollen season. Full disease-modifying benefit — the kind that persists years after stopping treatment — requires completing at least 3 years of consistent treatment, as established by multiple clinical trials. The 2017 GRASS trial (Scadding et al., JAMA) showed that 2-year SLIT courses did not produce durable post-treatment benefit, confirming the 3-year minimum. Marogna et al. (JACI, 2010) followed patients for 15 years and found that 3-year SLIT courses produced approximately 7 years of post-treatment benefit. Starting SLIT drops consistently and completing the full course is more important than the speed of early response.

For FDA-approved SLIT tablets, the first dose must be administered in a healthcare setting with 30-minute observation — this is required on the FDA labels for all four approved tablets because rare but serious systemic reactions can occur, particularly with the first dose. All subsequent doses are self-administered at home. For custom-compounded SLIT drops, the protocol varies by prescribing provider; most require a comprehensive allergy evaluation first, with drops then self-administered at home daily. Allergy shots historically meant 57-60 clinic visits over 3 years, but at-home SCIT programs like Curex now eliminate most of that in-office time: after a comprehensive evaluation, eligible patients self-inject at home, with the first dose and every dose change supervised live over Zoom by the prescribing allergist.

The most common side effects of SLIT are local oral reactions — itching of the mouth, tongue, or throat, which affects 25-67% of patients depending on the allergen tablet, typically beginning within the first week and declining after 2-4 weeks of consistent dosing. Mild swelling of the lips, tongue, or palate occurs in roughly 10-20% of patients. GI symptoms including stomach discomfort occur in 5-15%, more commonly with the dust mite tablet (Odactra). Serious systemic reactions are rare: the pooled SLIT-tablet analysis (Nolte et al., 2024) found only 3 treatment-related anaphylaxis cases out of over 8,200 patients — approximately 0.02% — and none were life-threatening. Zero fatalities have ever been documented from SLIT worldwide. All SLIT prescriptions include auto-injectable epinephrine as a precaution.

Evidence suggests allergy drops — like allergy shots — produce disease-modifying benefits that persist after stopping treatment, provided the course is at least 3 years in duration. Durham et al. (JACI, 2010, 2012) confirmed sustained improvement 1-2 years after completing a 3-year grass SLIT-tablet course. Marogna et al. (JACI, 2010) followed 59 patients on SLIT drops for 15 years and found that a 3-year course produced approximately 7 years of post-treatment benefit, with a 4-year course extending this to approximately 8 years. Critically, the 2017 GRASS trial (Scadding et al., JAMA, 2017) showed that a 2-year course of SLIT produced no significant post-treatment benefit, confirming the 3-year threshold. Shorter courses may provide symptom relief during treatment without producing the immune memory needed for lasting post-treatment protection.

Allergy drops and tablets have an excellent safety record in children and are often preferred over allergy shots for pediatric patients due to the absence of needles and a dramatically better safety profile. The most recent large pediatric trial (Roberts et al., Lancet Regional Health Europe, 2024), enrolling 1,460 children aged 5-11 on HDM SLIT-tablet, reported no treatment-related serious adverse events, no anaphylaxis, and no epinephrine use. Halken et al. (J Allergy Clin Immunol Pract, 2020), pooling 9 pediatric SLIT-tablet RCTs involving 1,818 children, found only 7 treatment-related serious adverse events and 3 epinephrine administrations across the entire dataset. FDA-approved Odactra was expanded in February 2025 to include children aged 5-11. For younger children, custom SLIT drops are often prescribed off-label by allergists based on the European evidence base.